insulin glulisine 100 units/ml solution for injection in a pre-filled pen (Apidra® SoloStar®) (No: 457/08)

Sanofi-aventis

Product Update

07 March 2008

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

insulin glulisine 100 units/ml solution for injection in a pre-filled pen (Apidra® Solostar®) is accepted for restricted use within NHS Scotland for the treatment of adult patients with diabetes mellitus in whom treatment with this insulin analogue is appropriate and in whom the use of a pre-filled pen offers advantages over a pen and cartridge device.

Insulin glulisine has similar efficacy to other short-acting insulins in reducing glycated haemoglobin and a similar pharmacokinetic profile to at least one other insulin analogue. It is restricted to use in patients where regular human insulin is inappropriate.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 16th January 2008.

Chairman,
Scottish Medicines Consortium

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6989
E-mail: rosie.murray@nhs.net

Chairman Professor David Webb